Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05911360 · ClinicalTrials.gov registry record · Phase 3
A Study to Evaluate Efficacy, Safety and Tolerability in Antiretroviral Therapy (ART)-Experienced Participants of at Least 50 Years of Age Living With Human Immunodeficiency Virus (HIV) With Virologic Suppression Who Switch to DTG/3TC FDC From BIC/FTC/TAF
A Phase 3 study of HIV Infections and HIV, sponsored by ViiV Healthcare.
- Active
- Registry status
- Phase 3
- Development phase
- 205
- Enrollment target
- 20
- Study locations
NCT05911360 is a Phase 3 study of HIV Infections and HIV that is active but no longer recruiting, run by ViiV Healthcare. The registered enrollment target is 205 participants, below the 445-participant average among 542 other HIV Infections trials with a reported enrollment target (54% lower). The trial reports 20 study locations across 12 states.
The verdict
NCT05911360, a Phase 3 study of HIV Infections and HIV, is active but no longer recruiting, sponsored by ViiV Healthcare.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 205 participants
- Enrollment target
- 20
- Study locations
Study Summary
The study aims at evaluating the maintenance of virologic suppression of dolutegravir/lamivudine (DTG/3TC) fixed dose combination (FDC) at Week 48 post-switch from bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) in participants living with Human Immunodeficiency Virus Type 1 (HIV-1) who are of at least 50 years of age and above.
Conditions Studied
Interventions
- DRUG DTG/3TC
Study Locations (20)
Florida
- GSK Investigational Site - Ft. Pierce
- GSK Investigational Site - Miami
- GSK Investigational Site - West Palm Beach
Georgia
- GSK Investigational Site - Augusta
- GSK Investigational Site - Decatur
- GSK Investigational Site - Macon
North Carolina
- GSK Investigational Site - Charlotte
- GSK Investigational Site - Greensboro
- GSK Investigational Site - Wilmington
California
- GSK Investigational Site - Bakersfield
- GSK Investigational Site - Palm Springs
Michigan
- GSK Investigational Site - Berkley
- GSK Investigational Site - Detroit
Arizona
- GSK Investigational Site - Phoenix
District of Columbia
- GSK Investigational Site - Washington D.C.
Massachusetts
- GSK Investigational Site - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 205 participants |
| Start Date | 2023-01-31 |
| Est. Completion | 2026-01-13 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05911360
The ClinicalTrials.gov registry entry for NCT05911360 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 205 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 445-participant average among 542 other HIV Infections trials with a reported enrollment target (54% lower). The listed sponsor is ViiV Healthcare, which has 182 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with HIV Infections appearing as the primary indexed condition, and to 1 intervention - of which DTG/3TC is the first listed.
NCT05911360 reports 20 study locations spanning 12 distinct geographic areas - top geographies include Florida, Georgia, North Carolina.
Frequently Asked Questions
What is clinical trial NCT05911360 about?
NCT05911360 is a clinical study titled "A Study to Evaluate Efficacy, Safety and Tolerability in Antiretroviral Therapy (ART)-Experienced Participants of at Least 50 Years of Age Living With Human Immunodeficiency Virus (HIV) With Virologic Suppression Who Switch to DTG/3TC FDC From BIC/FTC/TAF". The study aims at evaluating the maintenance of virologic suppression of dolutegravir/lamivudine (DTG/3TC) fixed dose combination (FDC) at Week 48 post-switch from bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) in participants living with Human Immunodeficiency Virus Type 1 (HIV-1) wh...
What is the current status of trial NCT05911360?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 205 participants. The study started on 2023-01-31. Estimated completion is 2026-01-13.
What conditions does trial NCT05911360 study?
This clinical trial studies the following conditions: HIV Infections, HIV.
What interventions are being tested in trial NCT05911360?
The interventions under investigation include: DTG/3TC (DRUG).
Who is sponsoring clinical trial NCT05911360?
This trial is sponsored by ViiV Healthcare, which has 182 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05911360 being conducted?
This trial has 20 study locations across Arizona, California, District of Columbia, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for HIV Infections
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Evaluate the Effectiveness of Long-acting (LA) Cabotegravir (CAB) + Rilpivirine (RPV) LA When Given to Participants With Detectable HIV-1
RECRUITING · Phase 3
-
Testing a Real-time Electronic Antiretroviral Adherence Monitoring Intervention
RECRUITING · Phase 3
-
SmartSteps: A Context-Aware, PrEP Adherence Intervention for Individuals With Substance Use Disorder
RECRUITING · Phase 3
-
Study Evaluating the Efficacy, Safety, and Tolerability of Switching to Long-acting Cabotegravir Plus Long-acting Rilpivirine From Current Antiretroviral Regimen in Virologically Suppressed HIV-1-infected Adults
ACTIVE NOT RECRUITING · Phase 3
-
The LATITUDE Study: Long-Acting Therapy to Improve Treatment SUccess in Daily LifE
ACTIVE NOT RECRUITING · Phase 3
-
Efficacy, Safety and Tolerability Study of Long-acting Cabotegravir Plus Long-acting Rilpivirine (CAB LA + RPV LA) in Human-immunodeficiency Virus-1 (HIV-1) Infected Adults
ACTIVE NOT RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.